{
  "docId": "019de075-f154-767b-9f07-479a2da3f64b",
  "docSlug": "d4796e91221d5758021de97ee63957e0",
  "documentTitle": "Exscientia | Investor Presentation Deck | 69 slides",
  "authorId": "exscientia",
  "authorName": "Exscientia",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 31,
  "pageCount": 69,
  "prevPage": 30,
  "nextPage": 32,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "overcrowded",
  "nDataPoints": 4,
  "notes": "The slide outlines a standard clinical trial progression from dose escalation to expansion, with a focus on establishing RP2D and evaluating ORR.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-f154-767b-9f07-479a2da3f64b/31",
  "deckHref": "/decks/019de075-f154-767b-9f07-479a2da3f64b",
  "deckJsonHref": "/decks/019de075-f154-767b-9f07-479a2da3f64b.json",
  "deckAnchorHref": "/decks/019de075-f154-767b-9f07-479a2da3f64b#slide-31",
  "components": [
    {
      "bbox": {
        "h": 0.07,
        "w": 0.25,
        "x": 0.61,
        "y": 0.58
      },
      "kind": "callout",
      "text": "Primary efficacy endpoint: ORR",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5809df9b-6887-40c2-8002-fffc8feaf907",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.665,
        "x": 0.247,
        "y": 0.338
      },
      "kind": "diagram",
      "text": "Part 1: Dose Escalation to Part 2: Dose Expansion",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ec1fdc7f-4839-48b8-afd9-74c500777987",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.9,
        "x": 0.05,
        "y": 0.89
      },
      "kind": "disclaimer",
      "text": "ELUCIDATE (protocol number GTAEXS617-001) is a Phase 1/2 open-label multi-centre study... *Solid tumours under consideration include ovarian cancer, pancreatic cancer, HR+ HER2- breast cancer, head & neck cancer, NSCLC and colorectal cancer",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2f766cf9-9e92-4050-8fce-11120cd4a9cc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.3,
        "x": 0.25,
        "y": 0.4
      },
      "kind": "list",
      "text": "Part A: Monotherapy; Part B: Combination with SoC; n=up to 30 patients; Data-informed prioritisation",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2326333b-932c-45fc-a264-779bb5a9548d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.3,
        "x": 0.61,
        "y": 0.4
      },
      "kind": "list",
      "text": "n=30-60 patients monotherapy; n=30-60 patients combination; n depends on cohorts",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fcb12beb-c59c-4ee0-a53c-6cc4242110db",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.77
      },
      "kind": "paragraph",
      "text": "Additional data generation, including clinical endpoints, peripheral and tumour multi-omics, and correlation of data and response to previously collected ex vivo results planned",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "342053d9-0de4-4688-9a96-7bb0389d0a92",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.7,
        "x": 0.07,
        "y": 0.13
      },
      "kind": "title",
      "text": "Preclinically identified PD biomarkers to be further assessed in the trial",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a836470b-352c-4cf3-86fb-8aadc7d7a9e8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.07,
        "y": 0.06
      },
      "kind": "title",
      "text": "ELUCIDATE: '617 Phase 1/2 ongoing in advanced solid tumours",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "251cf060-9093-464e-a3ae-6471ef4b56c9",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "clinical-trial-design",
      "slug": null,
      "matchId": "bd27a2fa-72c6-41dd-b402-78ccb1b0a9e7",
      "evidence": "Standard Phase 1/2 trial structure (Dose Escalation/Expansion)",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 69,
      "from": 8,
      "beatId": "96bf0b4a-a49b-4aee-bb3c-8a6ad1f87eda",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution (Provide relief)",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The deck presents Exscientia's solution, highlighting its AI-driven platform and its potential to improve clinical trial success rates.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 69,
      "from": 3,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "89204827-3a6d-41c5-9676-a9c3c4bc7a6d",
      "evidence": "The deck presents Exscientia's approach to precision medicine, highlighting its effectiveness.",
      "position": 1,
      "objective": "Why is Exscientia's approach to precision medicine effective?",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.7,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}